DrugPatentWatch Database Preview
Join the DrugPatentWatch Referral Program Get access to a free drug patent landscape report or a free one-month subscription
« Back to Dashboard
Summary for Patent: 8,691,506
|Title:||Gene expression profiles being predictive for the response of tumors to pharmaceutically effective compounds|
|Abstract:||The present invention relates to a method for providing a gene expression profile being predictive for the specific response of an individual tumor to a pharmaceutically effective compound, the use thereof, a microarray wherein the nucleotide sequences attached to the substrate consist of nucleotide sequences corresponding to the predictive genes of said gene expression profile, and a diagnostic kit containing said microarray.|
|Inventor(s):||Bausch; Niko (Freiburg, DE), Fiebig; Heinz-Herbert (Freiburg, DE), Korrat; Andre (Freiburg, DE), Maurer; Martina (Freiburg, DE), Metz; Thomas (Glottertal, DE), Schuler; Julia (Freiburg, DE)|
|Assignee:||Oncotest GmbH (Freiburg, DE)|
|Patent Claims:||1. A diagnostic kit containing a microarray, the microarray comprising the nucleotide sequences of SEQ ID NO.:1 to 118 attached to a substrate, the nucleotide
sequences corresponding to the predictive genes of a gene expression profile obtained by a method for providing a gene expression profile being predictive for the specific response of an individual tumor to Avastin, the method comprising the steps of:
(a) xenotransplanting human tumor material of at least five different tumors into at least one suitable test animal, (b) determining gene expression profiles of the resulting tumor xenografts, (c) treating said at least one test animal with Avastin, (d)
evaluating responsiveness of the tumor xenografts to Avastin, (e) identifying the gene expression profile of each of the tested tumor xenografts, and (f) determining the predictive genes in the gene expression profiles by comparing the gene expression
profiles of responsive tumors, no-change tumors and progressive tumors, wherein step (f) comprises the steps of (i) dividing the complete set of gene expression profiles of the tumor xenografts into sub-sets, each of the sub-sets missing one of said gene
expression profiles, (ii) determining the predictive genes in each sub-set, and (iii) obtaining the gene expression profile being predictive for the specific response of an individual tumor to Avastin by setting up the intersection of the predictive
genes of all sub-sets.
2. The kit according to claim 1, wherein in step (f) a tumor xenograft is considered to be responsive when its T/C (therapy/control) value is less than 25%.
3. The kit according to claim 1, wherein in step (f) a tumor xenograft is considered to be no-change when its T/C (therapy/control) value is ranges from 25% to 42%.
4. The kit according to claim 1, wherein in step (f) a tumor xenograft is considered to be progressive when its T/C (therapy/control) value is more than 42%.
5. The kit according to claim 1, wherein in step (ii) an expression profile of 300 genes is determined for each sub-set.
Summary for Patent: Start Trial
|Foriegn Application Priority Data|
|Foreign Country||Foreign Patent Number||Foreign Patent Date|
|05008088||Apr 13, 2005|
|PCT Filed||April 13, 2006||PCT Application Number:||PCT/EP2006/003421|
|PCT Publication Date:||October 19, 2006||PCT Publication Number:||WO2006/108659|
|Applicant||Tradename||Biologic Ingredient||Dosage Form||BLA||Number||Approval Date||Patent No.||Assignee||Estimated Patent Expiration||Status||Orphan||Source|
|Genentech||AVASTIN||bevacizumab||VIAL; INTRAVENOUS||125085||001||2004-02-26||Start Trial||Oncotest GmbH (Freiburg, DE)||2025-04-13||RX||Orphan||search|
|Genentech||AVASTIN||bevacizumab||VIAL; INTRAVENOUS||125085||002||2004-02-26||Start Trial||Oncotest GmbH (Freiburg, DE)||2025-04-13||RX||Orphan||search|
|>Applicant||>Tradename||>Biologic Ingredient||>Dosage Form||>BLA||>Number||>Approval Date||>Patent No.||>Assignee||>Estimated Patent Expiration||>Status||>Orphan||>Source|
|Country||Patent Number||Publication Date|
|World Intellectual Property Organization (WIPO)||2006108659||Apr 19, 2007|
|World Intellectual Property Organization (WIPO)||2006108659||Oct 19, 2006|
|United States of America||2011243925||Oct 06, 2011|
|European Patent Office||1869216||Aug 15, 2012|
|>Country||>Patent Number||>Publication Date|
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.